source
- Novartis board under fire as two late-stage trials fail and CAR-T program pausedNovartis' board is facing heightened investor scrutiny after the Swiss drugmaker reported failures in two pivotal late-phase trials, raising doubts about its capital deployment strategy for growth…
- Cancer drug shortages persist, hampering patient care and highlighting lasting impacts of platinum chemotherapyThe STAT+ newsletter reports that cancer treatment centers continue to struggle with ongoing shortages of key oncology drugs, forcing clinicians to alter or delay therapy for patients. These short…